Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Income Before Tax

Profit after all operating and non-operating items but before income tax.

Pelthos Therapeutics Inc.AMEX: PTHS

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$10.24M, compared with -$1.97M a year earlier. Trailing-twelve-month income before tax was -$58.98M.

Context

  • Income before tax amounted to 301.9% of revenue in FY2025.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$10.24M or moves back toward the trailing-twelve-month quarterly average of -$14.74M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.24M+64.2% QoQ
Last fiscal yearDec 2025
-$50.71M-537.4% YoY
LTMMar 2026
-$58.98M-701.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-420.3%——
1 year-537.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(50.71M) USD
Year-over-year change
-537.4%

Income Before Tax vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 income before tax of -$58.98M is the lowest of the 4 companies compared; the peer median is -$7.34M.
  • Its year-over-year change of -701.2% is the lowest of 4, against a peer median of -60.0%.
  • Income before tax amounts to 212.9% of revenue for PTHS.
PTHS Competitors Peer median
Income Before Tax for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$1.62B +10877.8%——
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026-$7.34M -120.7%——
CINGCingulate Inc.LTM Mar 2026-$27.71M -60.0%——
PTHSPelthos Therapeutics Inc.LTM Mar 2026-$58.98M -701.2%—212.9%
Peer median (excluding PTHS) -$7.34M-60.0%——

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000016.8M
Cost of Revenue00009.37M
Gross Profit00007.43M
Gross Margin————44.2%
Research & Development209.05K391.73K2.58M1.18M1.23M
Selling, General & Admin629.95K1.93M4.28M6.39M37.08M
Operating Expenses839K2.32M6.86M7.57M39.86M
Depreciation & Amortization00002.29M
EBITDA(595.13K)(2.32M)(6.86M)(7.17M)(45.41M)
EBITDA Margin————-270.4%
Operating Income(839K)(2.32M)(6.86M)(7.57M)(32.43M)
Operating Margin————-193.1%
Interest Income00005K
Interest Expense253140.43K518.51K786.39K3.01M
Other Income / Expenses243.61K(140.43K)(518.51K)(383.89K)(18.28M)
Income Before Tax(595.39K)(2.46M)(7.38M)(7.96M)(50.71M)
Pre-Tax Margin————-301.9%
Income Tax Expense0000(7.39M)
Net Income(595.39K)(2.46M)(7.38M)(7.96M)(43.32M)
Net Margin————-257.9%
EPS (Basic)(1.00)(4.26)(12.80)(13.54)(23.04)
EPS (Diluted)(1.00)(4.26)(12.80)(13.54)(23.04)
Weighted Avg Shares576.75K576.75K576.75K587.62K1.88M
Weighted Avg Shares (Diluted)576.75K576.75K576.75K587.62K1.88M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.